Baldwin Wealth Partners LLC MA Lowers Holdings in Novartis AG (NYSE:NVS)

Baldwin Wealth Partners LLC MA trimmed its stake in shares of Novartis AG (NYSE:NVS) by 14.2% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 41,420 shares of the company’s stock after selling 6,858 shares during the period. Baldwin Wealth Partners LLC MA’s holdings in Novartis were worth $4,617,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors also recently bought and sold shares of the company. Human Investing LLC acquired a new stake in shares of Novartis during the 4th quarter worth approximately $25,000. Raiffeisen Bank International AG acquired a new stake in Novartis during the fourth quarter valued at $25,000. Nexus Investment Management ULC purchased a new position in Novartis in the first quarter valued at $25,000. Union Bancaire Privee UBP SA acquired a new position in shares of Novartis in the fourth quarter worth about $27,000. Finally, Park Square Financial Group LLC purchased a new stake in shares of Novartis during the 4th quarter worth about $30,000. 13.12% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of research analysts have recently issued reports on NVS shares. Morgan Stanley initiated coverage on Novartis in a research report on Wednesday, February 12th. They set an “underweight” rating on the stock. UBS Group reaffirmed a “neutral” rating on shares of Novartis in a report on Thursday, February 13th. Finally, BNP Paribas raised shares of Novartis to a “strong-buy” rating in a research note on Tuesday, April 15th. Three equities research analysts have rated the stock with a sell rating, six have issued a hold rating, one has assigned a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Hold” and an average price target of $123.38.

Novartis Price Performance

Shares of NYSE NVS opened at $118.02 on Monday. The firm has a 50-day simple moving average of $110.62 and a 200-day simple moving average of $106.60. The company has a quick ratio of 0.84, a current ratio of 1.04 and a debt-to-equity ratio of 0.48. The stock has a market capitalization of $249.31 billion, a price-to-earnings ratio of 20.07, a price-to-earnings-growth ratio of 1.70 and a beta of 0.59. Novartis AG has a 52 week low of $96.06 and a 52 week high of $120.92.

Novartis (NYSE:NVS) last released its quarterly earnings data on Tuesday, April 29th. The company reported $2.28 EPS for the quarter, beating analysts’ consensus estimates of $2.12 by $0.16. The company had revenue of $13.23 billion during the quarter, compared to the consensus estimate of $12.92 billion. Novartis had a net margin of 23.56% and a return on equity of 37.24%. Novartis’s quarterly revenue was up 11.9% on a year-over-year basis. During the same quarter in the prior year, the firm earned $1.80 EPS. On average, equities analysts predict that Novartis AG will post 8.45 earnings per share for the current fiscal year.

Novartis Company Profile

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology.